Saniona begins Phase IIa of Tesomet for Prader-Willi syndrome

Saniona AB (SSE:SANION) began the double-blind, placebo-controlled, Czech and Hungarian Phase IIa TM002 trial to evaluate 0.5 mg/50 mg Tesomet tesofensine/metoprolol once daily for 12 weeks in up to 30 patients with Prader-Willi syndrome. The trial’s first part will enroll 10-15 adults. Pending a DSMB review, a second part will enroll 10-15 adolescents. The primary endpoint is the change from baseline in body weight at week 12. Other endpoints include safety, pharmacokinetics, eating behavior, body composition and metabolic parameters...